S100A8 and juvenile idiopathic arthritis: The finding that clinicians reported that for patients with clinically inactive disease and an elevated MRP8/14 result (> 4000 ng/ml), none would advise withdrawal of MTX, and the observation that some patients in our cohort who had an elevated MRP8/14 value did not flare after stopping MTX for non-disease-related reasons (e.g., drug intolerance) highlights the need for further biomarkers to predict the risk of flare off medication in JIA and aid clinicians in treatment decisions.